Agomelatine (AGO178C)

DRUG2 trials

Sponsors

Novartis Pharmaceuticals

Conditions

Major Depressive Disorder

Phase 3

Efficacy, Safety and Tolerability of Agomelatine Sublingual Tablets in the Treatment of Major Depressive Disorder (MDD)

CompletedNCT01110902

Novartis PharmaceuticalsMajor Depressive Disorder

Start: 2010-05-31End: 2011-06-30Updated: 2020-12-24

Efficacy, Safety and Tolerability of Agomelatine Sublingual Tablets in the Treatment of Major Depressive Disorder

CompletedNCT01110889

Novartis PharmaceuticalsMajor Depressive Disorder

Start: 2010-05-31Updated: 2020-12-23